Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

18 Feb 2016

Abstract excerpt

BACKGROUND: Tafenoquine (TQ) and primaquine (PQ) are 8-aminoquinolines (8-AQ) with anti-hypnozoite activity against vivax malaria. PQ is the only FDA-approved medicine for preventing relapsing Plasmodium vivax infection and TQ is currently in phase 3 clinical trials for the same indication. Recent studies have provided evidence that cytochrome P450 (CYP) metabolism via CYP2D6 plays a role in PQ efficacy against...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Malaria Research and Control
Share to Pharmacogenetics and Drug Metabolism
Share to Trypanosoma species research and implications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26888075
DOI: 10.1186/s12936-016-1145-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trialPMID 26888075Read ↗

Impact of CYP2D6 Genetic Variation on Radical Cure of Plasmodium vivax Malaria.Semantic proximity Read ↗

Differential impact of Tafenoquine and Primaquine on Plasmodium vivax recurrence: the role of CYP2D6 variants.Semantic proximity Read ↗

Reduced cytochrome P-450 (CYP) 2D6 activity and Plasmodium vivax malaria risk in Amazonians: A retrospective, population-based cohort study.Semantic proximity Read ↗

Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses.Semantic proximity Read ↗

Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for LatentPlasmodium vivaxMalariaSemantic proximity Read ↗

Polymorphisms in Cytochrome P450 genes: implications for Plasmodium vivax malaria treatment in Brazil.Semantic proximity Read ↗

Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria.Semantic proximity Read ↗

Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.Semantic proximity Read ↗

Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function.Semantic proximity Read ↗

Pharmacogenetic Profiling of Cytochrome P450 Enzymes in Plasmodium vivax Patients Treated with Chloroquine and Primaquine: Implications for Personalized Malaria Therapy.Semantic proximity Read ↗

CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study.Semantic proximity Read ↗

Efficacy of Primaquine for the Radical Cure of Plasmodium vivax Malaria in Northeast Myanmar and the Impact of Cytochrome P450 2D6 Genotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.